CCCC Latest Press Releases

-- September 3, 2026 --

C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting Globe Newswire 7:00 AM

-- August 11, 2026 --

C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights Globe Newswire 7:00 AM

-- August 10, 2026 --

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- June 11, 2026 --

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population Globe Newswire 7:00 AM

-- May 20, 2026 --

C4 Therapeutics to Participate in Upcoming Conferences Globe Newswire 7:00 AM

-- May 18, 2026 --

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- May 12, 2026 --

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software